Treatment of inflammatory bowel disease (IBD)

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 629-642

  Pithadia, Anand B ^a   Jain, Sunita ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

5 aminosalicylates; Corticosteroids; Inflammatory bowel disease (ibd); Infliximab

Indexed keywords

AMINOSALICYLIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; BALSALAZIDE; BISMUTH SALT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; FISH OIL; FLUTICASONE; FOLIC ACID; HERBACEOUS AGENT; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MONOCLONAL ANTIBODY; OLSALAZINE; PREDNISOLONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; THALIDOMIDE; TIXOCORTOL; UNINDEXED DRUG;

CONSERVATIVE TREATMENT; CROHN DISEASE; DERMATITIS; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; EDEMA; ENTERITIS; EVENING DOSAGE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEUKOPENIA; LIVER FIBROSIS; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PREGNANCY OUTCOME; RASH; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 80051480268     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70575-8     Document Type: Review

References (64)

1. Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327. (Pubitemid 36929411)
2. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis, 2002, 8, 10-15. (Pubitemid 34130123)
3. Barnes PJ, Karin M: Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336, 1066-1071. (Pubitemid 27163860)
4. Bello C, Goldstein F, Thornton JJ: Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol, 1991, 86, 460-466.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol, 2005, 100, 1539-1546. (Pubitemid 41032360)
6. Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease, A meta-analysis adjusted for confounding variables. Gastroenterology, 1997, 113, 1465-1473. (Pubitemid 27461232)
7. Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, Kim YI: Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and β2-microglobulin-deficient mice. Cancer Epidemiol Biomarkers Prev, 2003, 12, 1262-1267. (Pubitemid 37499455)
8. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet, 1994, 343, 1249-1252. (Pubitemid 24158045)
9. Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Riley DP, Salvemini D: Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur J Pharmacol, 2001, 432, 79-89. (Pubitemid 33153136)
10. Dotan I, Rachmilewitz D: Probiotics in inflammatory bowel disease, possible mechanisms of action. Curr Opin Gastroenterol, 2005, 21, 426-430. (Pubitemid 40961168)
11. Farrell RJ, Alsahli M., Jeen YT, Falchuk K, Peppercorn M, Michetti P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease, A randomized, controlled trial. Gastroenterology, 2003, 124, 917-924. (Pubitemid 36389794)
12. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N et al.: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology, 2000, 118, 279-288. (Pubitemid 30067501)
13. Faubion WA Jr, Loftus EV, Harmsen WS, Zinmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease, a population-based study. Gastroenterology, 2001, 121, 255-260. (Pubitemid 32729372)
14. Feagan BG, McDonald J, Hopkins M: A randomised controlled trial of methotrexate (MTX) as a maintenance therapy for chronically active Crohn's disease (CD). New Eng J Med, 2000, 342, 1627-1632.
15. Fernandes-Banares F, Hinojoso J, Sanchez-Lombrana JL: Randomised clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol, 1999, 2, 427-433.
16. Fiocchi C: Inflammatory bowel disease, etiology and pathogenesis. Gastroenterology, 1998, 115, 182-205.
17. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present D: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease, Aretrospective cohort study. Gastroenterology, 2003, 124, 9-17. (Pubitemid 36055333)
18. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis, a randomised controlled pilot trial. Gut, 2005, 54, 242-249. (Pubitemid 40139241)
19. Gionchetti P, Rizzello F, Helwig U: Prophylaxis of pouchitis onset with probiotic therapy, a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124, 1202-1209. (Pubitemid 36531796)
20. Greenberg GR, Feagan BR, Martin F, Sutherland L, Thomson A, Williams N, Nilsson L, Persson T: Oral budesonide for active Crohn's disease. New Eng J Med, 1994, 331, 836-841. (Pubitemid 24289710)
21. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 1994, 344, 859-861.
22. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol, 2003, 15, 697-698. (Pubitemid 36688235)
23. Haber CJ, Meltzer SJ, Present DH, Koreitz BI: Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology, 1986, 91, 982-996.
24. Hanauer SB, Baert F: Medical therapy of inflammatory bowel disease. Med Clin North Am, 1994, 78, 1413-1426. (Pubitemid 24359177)
25. Hawthorne AB, Daneshmend T, Hawkey C, Belluzzi A, Everitt S, Holmes G, Malkinson C et al.: Treatment of ulcerative colitis with fish oil supplementation, a prospective 12 month randomized controlled trial. Gut, 1992, 33, 922-928.
26. Herias MV, Koninkx JF, Vos JG, Huis in't Veld JH, van Dijk JE: Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J Food Microbiol, 2005, 25, 103, 143-155. (Pubitemid 41080476)
27. Hofer KN: Oral budesonide in management of Crohn's disease. Ann Pharmacother, 2003, 37, 1457-1464.
28. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR: Influence of dietary factors on the clinical course of ulcerative colitis, a prospective cohort study. Gut, 2004, 53, 1479-1484. (Pubitemid 39265269)
29. Karimi O, Pena AS, van Bodegraven AA: Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease, a pilot study. Drugs Today (Barc), 2005, 41, 453-459. (Pubitemid 41447453)
30. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL: Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol, 1993, 88, 1198-1205. (Pubitemid 23219712)
31. Korelitz BI, Hanauer S, Rutgeerts P: Post-operative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn's disease, a 2-year multicenter trial. Gastroenterology, 1998, 114, A4141.
32. Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS: Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease, an in vitro study. Aliment Pharmacol Ther, 2002, 16, 197-205. (Pubitemid 34146360)
33. Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS: Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther, 2004, 19, 739-747. (Pubitemid 38496639)
34. Langmead L, Makins RJ, Rampton DS: Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther, 2004, 19, 521-527. (Pubitemid 38387178)
35. Lichtinger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 1994, 330, 1841-1845. (Pubitemid 24188135)
36. Macfarlane S, Furrie E, Kennedy A, Cummings JH, Macfarlane GT: Mucosal bacteria in ulcerative colitis. Br J Nutr, 2005, 93, S67-72. (Pubitemid 43073410)
37. MacLean CH, Mojica WA, Newberry SJ, Pencarz J, Garland RH, Tu W, Hilton LG et al.: Systematic review of the effects of omega-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr, 2005, 82, 611-619.
38. Malolepszy J, Kuczymska-Sekieta K, Chachaj W: Sodium cromoglycate therapy in ulcerative colitis. Acta Allergol, 1977, 13, 82-86 (Pubitemid 8261432)
39. Mazzon E, Muia C, Di Paola R, Genevose T, De Sarro A, Cuzzocrea S: Thalidomide treatment reduces colon injury induced by experimental colitis. Shock, 2005, 23, 556-564. (Pubitemid 40677430)
40. Meister D, Ghosh S: Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture, differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol, 2005, 21, 11, 7466-7472. (Pubitemid 43126028)
41. Meyers S, Sachar DB: Medical therapy of Crohn's disease. In: Inflammatory Bowel Disease. 4th edn., Eds. Kersnar JB, Shorter RG, Williams and Wilkins, Baltimore, 1995, 695-714.
42. Middleton SJ, Naylor S, Woolner J, Hunter JO: A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther, 2002, 16, 1131-1135. (Pubitemid 34680756)
43. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinsonn AM, Chao J et al: Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther, 2010, 31, 1296-1309.
44. Papadakis KA, Targan SR: The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis, 2000, 6, 303-313.
45. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med, 1995, 123, 132-142.
46. Prantera C, Cottone M, Pallone F: Mesalamine in the treatment of mild to moderate active Crohn's ileitis, results of a randomised multicenter trial. Gastroenterology, 1999, 116, 521-526. (Pubitemid 29106758)
47. Present DH, Rutgeerts P, Targan S, Hanauer S, Mayer L, Hogezand R, Podolsky D: Infliximab for the treatment of fistulas in patients with Crohn's disease. New Eng J Med, 1999, 340, 1398-1405. (Pubitemid 29205403)
48. Rutgeerts P, Feagan BF, Lichtenstein GR, Mayer L, Schreiber S, Colombel J, Rachmilewitz D et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology, 2004, 126, 402-413. (Pubitemid 38182297)
49. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology, 1995, 108, 1617-1621.
50. Ryder SD, Walker RJ, Jones H, Rhodes JM: Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther, 1990, 4, 333-338. (Pubitemid 20268684)
51. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y et al.: Dietary risk factors for inflammatory bowel disease, a multicenter case-control study in Japan. Inflamm Bowel Dis, 2005, 11, 154-163. (Pubitemid 40711220)
52. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis, 1995, 1, 48-63.
53. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 2007, 357, 228-238. (Pubitemid 47080387)
54. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MAet al.: Infliximab maintenance therapy for fistulizing Crohn's disease. New Engl J Med, 2004, 350, 876-885. (Pubitemid 38252535)
55. Sartor RB: Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am, 1995, 24, 475-485.
56. Sartor RB: Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. In: Inflammatory Bowel Disease. 5th edn., Eds. Kirsner JB, Hanauer S, Saunders, Philadelphia, 1999, 153-178.
57. Shah SB, Hanauer SB: Treatment of diarrhea in patients with inflammatory bowel disease, concepts and cautions. Rev Gastroenterol Disord, 2007, 7, S3-10.
58. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO: Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, 2003, CD000301.
59. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R et al.: Double blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut, 1991, 32, 1071-1075.
60. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present D, Braakman T, DeWoody K et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. New Eng J Med, 1997, 337, 1029-1035.
61. Taylor BS, Shao L, Gambotto A, Ganster RW, Geller DA: Inhibition of cytokine-induced nitric oxide synthase expression by gene transfer of adenoviral IκBα. Surgery, 1999, 126, 142-147. (Pubitemid 29382773)
62. Vakil N, Sparberg M: Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology, 1989, 96, 62-67. (Pubitemid 19046267)
63. Vasiliauskas EA, Kam LY, Abreu MT: An open-label, step-wise dose-escalating pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology, 1999, 117, 1278-1287.
64. Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest, 1998, 101, 1163-1174. (Pubitemid 28125296)